Bausch Health Companies (BHC)
Market Price (12/23/2025): $6.99 | Market Cap: $2.6 BilSector: Health Care | Industry: Pharmaceuticals
Bausch Health Companies (BHC)
Market Price (12/23/2025): $6.99Market Cap: $2.6 BilSector: Health CareIndustry: Pharmaceuticals
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% | Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -86% | Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 772% |
| Attractive yieldFCF Yield is 43% | Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 26x | |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Geriatric Care. | Key risksBHC key risks include [1] its substantial debt burden, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 11% |
| Attractive yieldFCF Yield is 43% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, and Geriatric Care. |
| Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -86% |
| Debt is significantNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 772% |
| Expensive valuation multiplesP/EPrice/Earnings or Price/(Net Income) is 26x |
| Key risksBHC key risks include [1] its substantial debt burden, Show more. |
Why The Stock Moved
Qualitative Assessment
AI Analysis | Feedback
Between approximately August 31, 2025, and December 23, 2025, Bausch Health Companies (BHC) experienced a -5.8% movement due to several key factors.1. Persistent High Debt Load: Bausch Health continued to be weighed down by its substantial debt obligations. As of September 30, 2025, the company's long-term debt amounted to $21 billion, which remained a significant concern for investors and limited its financial flexibility.
2. Major Investor Divestment: Carl Icahn's hedge fund, a notable activist investor, divested from Bausch Health in Q3 2025. This move by a major financial player likely signaled a loss of confidence and put downward pressure on the stock.
Show more
Stock Movement Drivers
Fundamental Drivers
The 2.6% change in BHC stock from 9/22/2025 to 12/22/2025 was primarily driven by a 2.6% change in the company's P/E Multiple.| 9222025 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 6.81 | 6.99 | 2.64% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 9858.00 | 9858.00 | 0.00% |
| Net Income Margin (%) | 0.99% | 0.99% | 0.00% |
| P/E Multiple | 25.77 | 26.46 | 2.64% |
| Shares Outstanding (Mil) | 370.90 | 370.90 | 0.00% |
| Cumulative Contribution | 2.64% |
Market Drivers
9/22/2025 to 12/22/2025| Return | Correlation | |
|---|---|---|
| BHC | 2.6% | |
| Market (SPY) | 2.7% | 13.9% |
| Sector (XLV) | 13.7% | 26.9% |
Fundamental Drivers
The 14.6% change in BHC stock from 6/23/2025 to 12/22/2025 was primarily driven by a 13.5% change in the company's P/S Multiple.| 6232025 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 6.10 | 6.99 | 14.59% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 9731.00 | 9858.00 | 1.31% |
| P/S Multiple | 0.23 | 0.26 | 13.51% |
| Shares Outstanding (Mil) | 369.60 | 370.90 | -0.35% |
| Cumulative Contribution | 14.59% |
Market Drivers
6/23/2025 to 12/22/2025| Return | Correlation | |
|---|---|---|
| BHC | 14.6% | |
| Market (SPY) | 14.4% | 11.2% |
| Sector (XLV) | 18.0% | 32.0% |
Fundamental Drivers
The -6.4% change in BHC stock from 12/22/2024 to 12/22/2025 was primarily driven by a -9.5% change in the company's P/S Multiple.| 12222024 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 7.47 | 6.99 | -6.43% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 9474.00 | 9858.00 | 4.05% |
| P/S Multiple | 0.29 | 0.26 | -9.46% |
| Shares Outstanding (Mil) | 368.40 | 370.90 | -0.68% |
| Cumulative Contribution | -6.43% |
Market Drivers
12/22/2024 to 12/22/2025| Return | Correlation | |
|---|---|---|
| BHC | -6.4% | |
| Market (SPY) | 16.9% | 29.8% |
| Sector (XLV) | 14.5% | 38.6% |
Fundamental Drivers
The 10.4% change in BHC stock from 12/23/2022 to 12/22/2025 was primarily driven by a 192.8% change in the company's P/E Multiple.| 12232022 | 12222025 | Change | |
|---|---|---|---|
| Stock Price ($) | 6.33 | 6.99 | 10.43% |
| Change Contribution By | LTM | LTM | |
| Total Revenues ($ Mil) | 8127.00 | 9858.00 | 21.30% |
| Net Income Margin (%) | 3.13% | 0.99% | -68.19% |
| P/E Multiple | 9.03 | 26.46 | 192.84% |
| Shares Outstanding (Mil) | 362.50 | 370.90 | -2.32% |
| Cumulative Contribution | 10.37% |
Market Drivers
12/23/2023 to 12/22/2025| Return | Correlation | |
|---|---|---|
| BHC | -6.2% | |
| Market (SPY) | 47.7% | 27.8% |
| Sector (XLV) | 18.4% | 33.1% |
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BHC Return | -30% | 33% | -77% | 28% | 0% | -15% | -77% |
| Peers Return | 12% | 30% | 8% | 3% | 13% | 24% | 127% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 17% | 113% |
Monthly Win Rates [3] | |||||||
| BHC Win Rate | 42% | 50% | 25% | 50% | 42% | 42% | |
| Peers Win Rate | 50% | 58% | 57% | 45% | 50% | 57% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 73% | |
Max Drawdowns [4] | |||||||
| BHC Max Drawdown | -57% | 0% | -83% | -9% | -35% | -46% | |
| Peers Max Drawdown | -24% | -10% | -17% | -22% | -5% | -17% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: ABBV, JNJ, PFE, LLY, VTRS. See BHC Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/22/2025 (YTD)
How Low Can It Go
| Event | BHC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -86.7% | -25.4% |
| % Gain to Breakeven | 650.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -57.1% | -33.9% |
| % Gain to Breakeven | 133.1% | 51.3% |
| Time to Breakeven | 331 days | 148 days |
| 2018 Correction | ||
| % Loss | -49.5% | -19.8% |
| % Gain to Breakeven | 98.1% | 24.7% |
| Time to Breakeven | 66 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -43.0% | -56.8% |
| % Gain to Breakeven | 75.5% | 131.3% |
| Time to Breakeven | 280 days | 1,480 days |
Compare to JNJ, COO, EYE, STAA, PCRX
In The Past
Bausch Health Companies's stock fell -86.7% during the 2022 Inflation Shock from a high on 3/11/2021. A -86.7% loss requires a 650.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
AI Analysis | Feedback
```htmlHere are 1-2 brief analogies to describe Bausch Health Companies (BHC):
- Think of it as a diversified pharmaceutical company with a strong focus on eye health (through its Bausch + Lomb brand) and gastrointestinal products, similar to a more specialized Johnson & Johnson focusing on these specific healthcare areas.
- It's a diversified pharmaceutical company that includes a significant global eye care business (Bausch + Lomb), comparable to how AbbVie has its broad pharmaceutical portfolio plus its notable eye care division.
AI Analysis | Feedback
- Bausch + Lomb Eye Health Products: Offers a wide range of contact lenses, lens care solutions, and prescription medications for various eye conditions.
- Salix Pharmaceuticals Gastroenterology Products: Provides prescription medications for gastrointestinal disorders, including Xifaxan for IBS-D and hepatic encephalopathy.
- Ortho Dermatologics Skincare Products: Delivers prescription treatments for dermatological conditions such as acne, rosacea, and psoriasis.
- Neurology and Other Specialty Products: Encompasses prescription medications addressing neurological disorders and other specialized health needs.
AI Analysis | Feedback
Bausch Health Companies (BHC) Major Customers
Bausch Health Companies primarily sells its pharmaceutical products, medical devices, and over-the-counter products to other companies. These direct customers then distribute or sell the products to healthcare providers, pharmacies, and ultimately, individual patients. Based on Bausch Health's financial disclosures, a significant portion of its U.S. gross product sales are to three major drug wholesalers. These major customers are:- AmerisourceBergen Corporation (Symbol: ABC)
- Cardinal Health, Inc. (Symbol: CAH)
- McKesson Corporation (Symbol: MCK)
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlThomas J. Appio, Chief Executive Officer
Thomas J. Appio was appointed Chief Executive Officer of Bausch Health Companies in May 2022. He previously served as the Company's President & Co-Head Bausch + Lomb/International and Executive Vice President, Company Group Chairman, International. Prior to Bausch Health's acquisition of Bausch + Lomb in 2013, Mr. Appio held several positions with Bausch + Lomb, including Vice President, North Asia/Japan and Managing Director, Greater China and Japan. Before joining Bausch + Lomb, he spent 23 years with Schering-Plough in various leadership and operations responsibilities across multiple countries and regions.
Jean-Jacques Charhon, Executive Vice President, Chief Financial Officer
Jean-Jacques Charhon joined Bausch Health Companies as Chief Financial Officer on August 19, 2024. He brings over 25 years of experience in financial leadership roles with both public and private companies across healthcare, high tech, and services. His previous experience includes roles at General Electric, Hewlett Packard, Novartis, and Purdue Pharma. Prior to joining Bausch Health, Mr. Charhon served as Executive Vice President and Chief Financial Officer at Signant Health.
Mirza Dautbegovic, Executive Vice President, Chief Operating Officer
Mirza Dautbegovic has served as Executive Vice President and Chief Operating Officer of Bausch Health Companies since 2022. Before this role, he was the Vice President, International Finance for the company. Earlier in his career, he held the position of Vice President and Chief Financial Officer at Tyco.
Seana Carson, Executive Vice President, General Counsel
Seana Carson joined Bausch Health in November 2006 and has been Executive Vice President, General Counsel since May 2022. Her prior roles at the company include Senior Vice President, Head of Legal International, and Senior Vice President and Chief Compliance Officer for over 12 years. Before joining Bausch Health, Ms. Carson began her career as an Associate with the Canadian legal firm Ogilvy Renault LLP.
Kathleen Fitzpatrick, Executive Vice President, Chief Human Resources and Communications Officer
Kathleen Fitzpatrick joined Bausch Health in 2019 as Vice President, Human Resources, and was appointed Executive Vice President, Chief Human Resources and Communications Officer in 2024. Prior to her time at Bausch Health, Ms. Fitzpatrick spent over 20 years with Honeywell, where she held positions of increasing responsibility across several business units and countries.
```AI Analysis | Feedback
Key Risks to Bausch Health Companies (BHC)
Bausch Health Companies (BHC) faces several significant risks, primarily driven by its substantial debt burden, the threat of generic competition to its key products, and ongoing litigation and regulatory challenges.1. High Debt and Leverage
Bausch Health carries a significant debt load, reported at approximately $21.5 billion as of the third quarter of 2024, with a concerning debt-to-capital ratio of 85% and a leverage ratio of around 7x. This high leverage is a major concern for investors and analysts, as it can limit the company's ability to invest in research and development, innovate, and bring new products to market, while also diverting cash flow towards interest payments. The company faces substantial debt maturities, particularly in the 2025-2026 period, with further significant payments anticipated in 2027-2028. The market has shown sensitivity to Bausch Health's financial structure, with stock volatility and past bankruptcy rumors highlighting the seriousness of its debt situation.2. Generic Competition, especially for Xifaxan
The company faces significant risks from potential generic competition, particularly concerning its key product, Xifaxan. Xifaxan has been a substantial revenue driver for Bausch Health, and the entry of generic alternatives, especially projected around 2027-2028, could lead to a rapid erosion of market share and pricing power. This threat places continuous pressure on the company to innovate and develop new products to offset potential revenue losses. Furthermore, Bausch Health is embroiled in legal disputes alleging antitrust violations by conspiring to delay a cheaper generic version of Xifaxan.3. Litigation and Regulatory Risks
Bausch Health has a history of legal challenges, including past accounting scandals and lawsuits. The company is currently facing legal action over alleged antitrust violations related to Xifaxan. Ongoing government investigations and various lawsuits present additional risks that could negatively impact the company's financial and strategic position. These legal and regulatory uncertainties can create significant financial liabilities and reputational damage.AI Analysis | Feedback
The emergence of gene therapies for eye diseases poses a clear threat to Bausch Health Companies, particularly through its significant retained stake in Bausch + Lomb. Bausch + Lomb's ophthalmic pharmaceutical portfolio includes numerous products for chronic eye conditions that require ongoing treatment.
Gene therapies, exemplified by existing approved treatments for certain inherited retinal diseases, offer the potential for one-time, curative interventions, fundamentally disrupting the long-term, chronic treatment model. As research and clinical development expand these therapies to more prevalent eye conditions (such as age-related macular degeneration or glaucoma), they represent a paradigm shift similar to how Apple's iPhone disrupted the traditional smartphone market. If widely adopted, these advanced therapies could significantly diminish the market demand for Bausch + Lomb's existing chronic ophthalmic drug products, thereby impacting Bausch Health's future revenue and valuation.
AI Analysis | Feedback
Here are the addressable markets for Bausch Health Companies' main products or services:
-
Bausch + Lomb (Eye Health)
- Glaucoma Treatment Market: The global glaucoma treatment market was valued at approximately USD 6.6 billion in 2024 and is projected to reach USD 6.9 billion in 2025. The U.S. glaucoma treatment market alone accounted for USD 2.24 billion in revenue in 2024.
- VYZULTA (for glaucoma): VYZULTA operates within the global ophthalmic market, which could reach $6.2 billion. The global glaucoma therapeutics market was approximately USD 4.8 billion in 2022.
- LUMIGAN (for glaucoma): This product is part of the global glaucoma treatment market, which was valued at approximately $4.5 billion in 2022, with North America holding over 45% of the global market share for glaucoma therapeutics in that year.
-
Salix Pharmaceuticals (Gastroenterology)
- XIFAXAN (rifaximin): The global rifaximin market size was valued at USD 1.84 billion in 2024 and is projected to increase to approximately USD 5.09 billion by 2034. North America held the largest share of 40% in the global rifaximin market in 2024. In 2022, XIFAXAN's global sales were estimated at approximately USD 830 million.
- Relistor (for opioid-induced constipation - OIC): The global opioid-induced constipation drugs market was valued at USD 2.87 billion in 2024 and is expected to reach USD 4.82 billion by 2032. The market for global opioid-induced constipation drugs is estimated to attain $4.2 billion by 2033.
-
Ortho Dermatologics (Dermatology)
- Bryhali (for psoriasis): Bryhali is a psoriasis treatment. The global psoriasis treatment market size was valued at USD 27.20 billion in 2024 and is projected to grow to USD 57.68 billion by 2032. In 2024, North America dominated this market with a 74.71% share.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Bausch Health Companies (BHC) over the Next 2-3 Years:
- Continued Growth in Key Segments (Salix and Solta Medical): Bausch Health anticipates sustained revenue growth from its established Salix (gastroenterology products) and Solta Medical (aesthetic medical devices) segments. The Salix segment, notably driven by products like Xifaxan, has shown consistent year-over-year growth. Solta Medical has also demonstrated significant organic growth, particularly in international markets such as South Korea and China.
- New Product Launches and Pipeline Advancements: The company's strategic focus on innovation and its robust pipeline are expected to drive future revenue. Key products mentioned include Cabtreo and Ryaltris, which have shown triple-digit growth. Furthermore, the Red Sea program, focused on a unique rifaximin formulation for cirrhosis treatment, and Larsucosterol, an FDA Breakthrough Therapy Designated asset for alcohol-associated hepatitis (acquired through DURECT Corporation), are significant late-stage pipeline assets with potential for future growth.
- International Market Expansion: Bausch Health is actively expanding its presence in new geographic markets. A notable example is the expansion of its OraPharma dental products business, including its flagship product Arestin, into Canada and Puerto Rico. The company is also bolstering its presence in high-growth regions like South Korea and China, particularly for its Solta Medical segment.
- Favorable Net Pricing and Product Mix: While not a new initiative, favorable net pricing across Bausch Health's diversified portfolio has contributed to improved gross margins and is expected to continue to support revenue. This has been observed with products like Xifaxan, which typically experiences mid-single-digit price increases year-over-year. The shift towards high-margin offerings, such as preservative-free eye drops, premium contact lenses, and surgical technologies, is also anticipated to enhance revenue and margins.
AI Analysis | Feedback
Share Repurchases
- Bausch Health Companies has not conducted significant share repurchases since 2017 due to its high debt burden.
- As of Q1 2025, management hinted at the possibility of resuming share buybacks once the debt burden is normalized.
Share Issuance
- In May 2022, Bausch Health executed an initial public offering (IPO) of its Bausch + Lomb eye health business, where a wholly owned subsidiary sold common shares of Bausch + Lomb.
- Bausch Health indirectly holds approximately 88% of Bausch + Lomb's outstanding common shares as of July 2025, following the IPO.
- Shareholders approved the Bausch Health Companies Inc. 2025 Employee Stock Purchase Plan ("ESPP") on May 13, 2025.
Outbound Investments
- Bausch Health completed the acquisition of DURECT Corporation in September 2025 for an upfront cash payment of approximately $63 million.
- The acquisition of DURECT Corporation aims to strengthen Bausch Health's hepatology pipeline, adding larsucosterol, a therapeutic molecule with FDA Breakthrough Therapy Designation for alcohol-associated hepatitis.
Capital Expenditures
- Bausch Health Companies' last 12-month capital expenditure was approximately $390.3 million.
- Capital expenditures are listed as one of the primary cash requirements for Bausch Health Companies in 2025.
Latest Trefis Analyses
Trade Ideas
Select ideas related to BHC. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11142025 | CRL | Charles River Laboratories International | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 17.4% | 17.4% | -3.7% |
| 11142025 | GDRX | GoodRx | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -6.7% | -6.7% | -11.8% |
| 11142025 | ASTH | Astrana Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 10.9% | 10.9% | -5.5% |
| 11142025 | SGRY | Surgery Partners | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.7% | 2.7% | -1.4% |
| 11072025 | TFX | Teleflex | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 11.4% | 11.4% | -5.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Bausch Health Companies
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 116.27 |
| Mkt Cap | 273.2 |
| Rev LTM | 56,451 |
| Op Inc LTM | 14,892 |
| FCF LTM | 5,988 |
| FCF 3Y Avg | 5,383 |
| CFO LTM | 12,008 |
| CFO 3Y Avg | 9,679 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.1% |
| Rev Chg 3Y Avg | 3.6% |
| Rev Chg Q | 6.0% |
| QoQ Delta Rev Chg LTM | 1.5% |
| Op Mgn LTM | 24.3% |
| Op Mgn 3Y Avg | 22.9% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 20.7% |
| CFO/Rev 3Y Avg | 18.3% |
| FCF/Rev LTM | 13.9% |
| FCF/Rev 3Y Avg | 13.1% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA216632 | CABTREO | adapalene | gel | 10202023 | 11.3% | 18.7% | 11.5% | -17.3% | -4.5% |
| NDA211882 | ARAZLO | tazarotene | lotion | 12182019 | -55.4% | -32.0% | -27.5% | -14.7% | -76.0% |
| NDA209354 | DUOBRII | halobetasol propionate | lotion | 4252019 | -0.9% | -4.5% | -28.7% | 25.0% | -70.5% |
| NDA209355 | BRYHALI | halobetasol propionate | lotion | 11062018 | -3.7% | -4.6% | -3.9% | -37.4% | -73.8% |
| NDA203567 | JUBLIA | efinaconazole | solution | 6062014 | -6.1% | 13.7% | 84.7% | -77.3% | -94.5% |
| NDA204153 | LUZU | luliconazole | cream | 11142013 | 33.9% | 17.2% | 26.8% | -28.8% | -93.4% |
| ANDA090715 | FENOFIBRATE | fenofibrate | tablet | 4052012 | -14.5% | 4.0% | 31.1% | 127.7% | -87.2% |
| NDA022483 | ZYCLARA | imiquimod | cream | 3252010 | 26.6% | 57.9% | 178.5% | 233.3% | -56.7% |
| NDA022436 | XERESE | acyclovir | cream | 7312009 | 14.0% | 29.7% | 118.3% | 439.5% | -31.5% |
| NDA050819 | ACANYA | benzoyl peroxide | gel | 10232008 | 19.3% | -3.3% | 68.9% | 257.5% | -1.2% |
| ... | |||||||||
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Pharmaceuticals | 3,909 | 3,642 | 3,763 | ||
| Devices | 1,997 | 1,872 | 1,903 | ||
| Over-the-counter (OTC) | 1,797 | 1,619 | 1,532 | ||
| Branded and Other Generics | 960 | 892 | 1,144 | ||
| Other revenues | 94 | 99 | 92 | ||
| Bausch + Lomb | 3,415 | ||||
| Diversified | 979 | 1,275 | |||
| International Rx | 1,181 | ||||
| Ortho Dermatologics | 548 | 565 | |||
| Salix | 1,904 | 2,022 | |||
| Bausch + Lomb/International | 4,739 | ||||
| Total | 8,757 | 8,124 | 8,434 | 8,027 | 8,601 |
Price Behavior
Price Behavior
| Market Price | $6.99 | |
| Market Cap ($ Bil) | 2.6 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -16.2% | |
| 50 Days | 200 Days | |
| DMA Price | $6.53 | $6.23 |
| DMA Trend | down | down |
| Distance from DMA | 7.0% | 12.3% |
| 3M | 1YR | |
| Volatility | 51.7% | 56.8% |
| Downside Capture | 45.56 | 69.27 |
| Upside Capture | 52.20 | 51.89 |
| Correlation (SPY) | 13.8% | 29.7% |
BHC Betas & Captures as of 11/30/2025
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.88 | 0.58 | 0.45 | 0.45 | 0.85 | 1.12 |
| Up Beta | -1.51 | 0.21 | 0.49 | -0.13 | 0.61 | 0.89 |
| Down Beta | -1.03 | 0.97 | 0.63 | 0.96 | 1.60 | 1.67 |
| Up Capture | 128% | 35% | -16% | 82% | 26% | 68% |
| Bmk +ve Days | 12 | 25 | 38 | 73 | 141 | 426 |
| Stock +ve Days | 8 | 17 | 25 | 59 | 114 | 360 |
| Down Capture | 196% | 68% | 86% | 11% | 84% | 103% |
| Bmk -ve Days | 7 | 16 | 24 | 52 | 107 | 323 |
| Stock -ve Days | 11 | 22 | 35 | 61 | 125 | 373 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Comparison of BHC With Other Asset Classes (Last 1Y) | |||||||
|---|---|---|---|---|---|---|---|
| BHC | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -9.0% | 13.6% | 14.7% | 67.3% | 6.8% | -0.5% | -16.6% |
| Annualized Volatility | 56.5% | 17.3% | 19.7% | 19.3% | 15.2% | 17.6% | 35.4% |
| Sharpe Ratio | 0.04 | 0.57 | 0.57 | 2.54 | 0.23 | -0.18 | -0.25 |
| Correlation With Other Assets | 38.9% | 30.6% | -1.1% | 23.3% | 33.2% | 11.6% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Comparison of BHC With Other Asset Classes (Last 5Y) | |||||||
|---|---|---|---|---|---|---|---|
| BHC | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -19.4% | 8.7% | 15.0% | 18.9% | 11.8% | 5.1% | 35.8% |
| Annualized Volatility | 60.3% | 14.5% | 17.1% | 15.5% | 18.7% | 18.9% | 48.9% |
| Sharpe Ratio | -0.10 | 0.42 | 0.71 | 0.98 | 0.51 | 0.18 | 0.63 |
| Correlation With Other Assets | 30.6% | 34.5% | 0.7% | 9.6% | 30.0% | 17.2% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Comparison of BHC With Other Asset Classes (Last 10Y) | |||||||
|---|---|---|---|---|---|---|---|
| BHC | Sector ETF | Equity | Gold | Commodities | Real Estate | Bitcoin | |
| Annualized Return | -22.9% | 10.0% | 14.9% | 14.9% | 6.7% | 5.5% | 69.9% |
| Annualized Volatility | 64.6% | 16.7% | 18.0% | 14.8% | 17.6% | 20.8% | 55.8% |
| Sharpe Ratio | -0.11 | 0.50 | 0.71 | 0.84 | 0.30 | 0.23 | 0.90 |
| Correlation With Other Assets | 36.9% | 37.1% | 0.5% | 16.2% | 30.3% | 12.5% | |
ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 10/29/2025 | 12.0% | 14.9% | 19.5% |
| 7/30/2025 | -7.8% | -9.9% | 11.9% |
| 4/30/2025 | 0.0% | -11.3% | -14.5% |
| 2/19/2025 | 10.3% | 18.3% | 9.5% |
| 10/30/2024 | 12.6% | 16.3% | 2.4% |
| 8/1/2024 | 1.2% | -13.4% | -2.7% |
| 5/2/2024 | -7.5% | -19.7% | -25.0% |
| 2/22/2024 | 7.3% | 6.1% | 9.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 13 | 12 | 15 |
| # Negative | 12 | 13 | 10 |
| Median Positive | 3.7% | 8.5% | 9.9% |
| Median Negative | -8.6% | -10.6% | -15.1% |
| Max Positive | 14.0% | 18.3% | 28.3% |
| Max Negative | -27.1% | -19.7% | -30.2% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 9302025 | 10302025 | 10-Q 9/30/2025 |
| 6302025 | 7312025 | 10-Q 6/30/2025 |
| 3312025 | 5012025 | 10-Q 3/31/2025 |
| 12312024 | 2202025 | 10-K 12/31/2024 |
| 9302024 | 10312024 | 10-Q 9/30/2024 |
| 6302024 | 8012024 | 10-Q 6/30/2024 |
| 3312024 | 5022024 | 10-Q 3/31/2024 |
| 12312023 | 2222024 | 10-K 12/31/2023 |
| 9302023 | 11022023 | 10-Q 9/30/2023 |
| 6302023 | 8032023 | 10-Q 6/30/2023 |
| 3312023 | 5042023 | 10-Q 3/31/2023 |
| 12312022 | 2232023 | 10-K 12/31/2022 |
| 9302022 | 11032022 | 10-Q 9/30/2022 |
| 6302022 | 8092022 | 10-Q 6/30/2022 |
| 3312022 | 5102022 | 10-Q 3/31/2022 |
| 12312021 | 2232022 | 10-K 12/31/2021 |
Insider Activity
Expand for More| Owner | Title | Filing Date | Action | Price | Shares | TransactedValue | Value ofHeld Shares | Form | |
|---|---|---|---|---|---|---|---|---|---|
| 0 | PAULSON & CO. INC. | 11282025 | Buy | 6.25 | 2,500,000 | 15,625,000 | 457,849,181 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.